|
|
|
| Research progress on the current treatment status and chemotherapeutic drugs of glioblastoma multiforme |
| HUANG Shulan LIU Yuhang WANG Hui WANG Chaojia |
| Department of Neurosurgery, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
|
Abstract Glioblastoma multiforme (GBM) is the most deadly type of heterogeneous brain tumor. The survival time of patients with pleomorphic glioblastoma is 8 to 15 months. GBM is driven by complex signaling pathways, the treatment of which has always been considered as the most challenging, the standard treatment for GBM includes surgery, radiation therapy, chemotherapy, and combination therapy. In this paper, the tumor interneoplasms of GBM and its heterogeneity and the latest chemotherapy drugs and mechanism are reviewed, this paper focuses on some natural synthesis and new anti-glioma drugs, which are also the main research focus of researchers today.
|
|
|
|
|
|
[1] Vred J，Desjard A，Hernd JE，et al. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma [J]. Clin CancerRes，2007，15（4）：1253-1259.
[2] Eckley M，Wargo KA. A review of glioblastomamultiforme [S]. Us Pharm，2010.
[3] Inda MM，Bonavia R，Seoane J，et al. Glioblastomamultiforme：a look inside its heterogeneous nature [J]. Cancers，2014，27（1）：226-239.
[4] Senft C，Bink，Franz K，et al. Intraoperative MRI guidance andextent of resection in glioma surgery：a randomized，controlled trial [J]. Lancet Oncol，2011，12（11）：997-1003.
[5] Anjum K，Abbas SQ，Akhter N，et al. Emerging biopharmaceuticals from bioactive peptides derived from marine organisms [J]. Chem Biol Drug Des，2017，90（1）：12-30.
[6] Leroy HA，Vermandel M，Lejeune JP，et al. Fluorescence guidedresection and glioblastoma in 2015：a review [J]. Lasers Surg Med，2015，47（5）：441-451.
[7] 毛承亮，唐凯，郑聪颖，等.荧光素钠引导下高级别胶质瘤的手术治疗[J].中国临床神经外科杂志，2017，22（2）：68-70.
[8] Cabrera AR，Kirkpatrick JP，Fiveash JB，et al. Radiation therapy for glioblastoma：executive summary of an american society for radiation oncology evidence-based clinical practice guideline [J]. Pract Radiat Oncol，2016，6（4）：217-225.
[9] Anjum K，Abbas SQ，Akhter N，et al. Emerging biopharmaceuticals from bioactive peptides derived from marine organisms [J]. Chem Biol，2017，90（1）：12-30.
[10] Vreden JJ，Desjardins A，Herndon JE，et al. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma [J]. Clin Cancer Res，2007，13（4）：1253-1259.
[11] Vredenburgh JJ，Desjardins A，Herndon JE，et al. Bevacizumab plus irinotecan in recurrent glioblastomamultiforme [J]. J Clin Oncol，2007，25（30）：4722-4729.
[12] Brada M，Stenning S，Gabe R，et al. Temozolomide versus procarbazinelomustine，and vincristine in recurrent highgrade glioma [J]. J Clin Oncol，2010，28（30）：4601-4608.
[13] Salazar M，Carracedo A，Salanueva J，et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells [J]. J Clin Invest，2009，119（5）：1359-1372.
[14] Dasari R，Masi M，Lisy R，et al. Fungal metabolite ophiobolin A as a promising anti-glioma agent：in vivo evaluation，structure-activity relationship and unique pyrrolylation of primary amines [J]. Bioorg Med Chem，2015，25（20）：4544-4548.
[15] Morrison R，Lodge T，Evidente A，et al. OphiobolinAasesterpenoid fungal phytotoxin，displays different mechanisms of cell death in mammalian cells depending upon the cancer cell origin [J]. Int J Oncol，2017，50（3）：773-786.
[16] Pais V，Danaila L，Pais E，et al. Ultrastructural patterns of the activated cell death programs in the human brain [J]. Ultrastruct，2013，37（2）：110-120.
[17] Valle B，Gómez D，Nieto-Sampedro M，et al. Synthesis and characterization of neurostatin-related compounds with high inhibitory activity of glioma growth [J]. Eur J Med Chem，2010，45（5）：2034-2043.
[18] Nieto M，Broderick JT. A soluble brain molecule related to epidermal growth factor receptor is a mitogen inhibitor for astrocytes [J]. J Neurosci，1989，22（1）：28-35.
[19] Kaufmann JK，Chiocca EA. Glioma virus therapies between bench and bedside [J]. Neuro Oncol，2014，16（3）：334-351.
[20] Murphy AM，Rabkin SD. Current status of gene therapy for brain tumors [J]. Transl Res，2013，161（4）：339-354.
[21] Swinnen JV，Roskams T，Joniau S，et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer [J]. Int J Cancer，2002，98（1）：19-22.
[22] Kuhajda FP. Fatty acid synthase and cancer：new application of an old pathway [J]. Cancer Res，2006，66（12）：5977-5980.
[23] Jiang P，Mukthavaram R，Chao Y，et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs [J]. J Transl Med，2014， 22（12）：12-13. |
|
|
|
